Some amphiphilic cations block the mitochondrial apoptosis-induced channel, MAC  by Martinez-Caballero, Sonia et al.
FEBS 28464 FEBS Letters 568 (2004) 35–38Some amphiphilic cations block the mitochondrial
apoptosis-induced channel, MACSonia Martinez-Caballero, Laurent M. Dejean, Kathleen W. Kinnally*
Department of Basic Sciences, College of Dentistry, New York University, 345 East 24th Street, New York, NY 10010, USA
Received 5 April 2004; revised 22 April 2004; accepted 7 May 2004
Available online 18 May 2004
Edited by Vladimir SkulachevAbstract The mitochondrial apoptosis-induced channel (MAC)
forms in the outer membrane of mitochondria early in apoptosis
and this activity is altered by physiological levels of cytochrome
c. While cyclosporine A and lidocaine have no eﬀect, dibucaine
induces a fast blockade of MAC with an IC50 of 39 lM. In
contrast, the IC50 for propranolol and triﬂuoperazine are 52 and
0.9 lM, respectively, and these drugs likely destabilize the open
state of MAC. These agents, and others not yet identiﬁed, should
be valuable tools in the study of apoptosis. Proﬁling MAC’s
pharmacology may generate novel therapeutic regimes for
disease.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Apoptosis is a phenomenon fundamental to higher eukary-
otes and essential to the mechanisms underlying tissue ho-
meostasis. The release of cytochrome c from mitochondria is
considered the commitment step of apoptosis in many cell
types and is tightly regulated by Bcl-2 family proteins [1–4].
While the permeability transition pore (PTP) is implicated in
cytochrome c release in some systems [5,6], recent investiga-
tions show that cytochrome c can exit directly through a pore
in the mitochondrial outer membrane without loss of outer
membrane integrity [6–13].
A high conductance channel forms in the mitochondrial
outer membrane early in apoptosis before the onset of other
apoptotic markers, e.g., Annexin-V labeling [7]. The appear-
ance of this mitochondrial apoptosis-induced channel (MAC)
is prevented by overexpression of Bcl-2 [13]. Furthermore, the
single channel activity of MAC is modiﬁed by physiological
levels of cytochrome c [7]. These ﬁndings support a role for
MAC in the release of cytochrome c and possibly other factors
early in apoptosis.
MAC is a novel channel with no previous pharmacological
proﬁle. Patch-clamp techniques were used in this study to ex-* Corresponding author. Fax: +1-212-995-4087.
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doi:10.1016/j.febslet.2004.05.006amine several potential eﬀectors. These data show that cyclo-
sporine A and lidocaine have no eﬀect, and the amphiphilic
cations propranolol, dibucaine and triﬂuoperazine are inhibi-
tors of MAC.2. Materials and methods
2.1. Cells and growth conditions
Parental FL5.12 cells were cultured as previously described [14] in
Iscove’s modiﬁed Eagle’s media (IMEM), 10% fetal bovine serum, 10%
WEHI-3B supplement (ﬁltered supernatant of WEHI-3B cells secreting
IL-3). Cultures were kept below 1.5 million cells/ml. Cells were washed
three times in media without IL-3 (WEHI supplement) to induce ap-
optosis 12 h prior to the isolation of mitochondria [7,13].
2.2. Isolation of mitochondria and preparation of proteoliposomes
Mitochondria were isolated from 2 to 15 g of FL5.12 cells as pre-
viously described for outer membrane preparations [7,13]. Outer
membranes were stripped from the inner membranes by French
pressing isolated mitochondria using modiﬁcations of the method of
Decker and Greenawalt [15]. French pressing was done at 2000 PSI in
460 mM mannitol, 140 mM sucrose, 2 mM EDTA, and 10 mM HE-
PES, pH 7.4. The pressed suspension was diluted 1:1 with 230 mM
mannitol, 70 mM sucrose, 1 mM EDTA, and 5 mM HEPES, pH 7.4,
and centrifuged at 10 000 rpm (12 000 g) for 10 min. Outer mem-
branes were separated from inner membranes as described by Man-
nella [16].
Proteoliposomes were formed by a modiﬁcation of the method of
Criado and Keller [7,13,17]. Brieﬂy, small liposomes were formed by
sonication of lipid (Sigma Type IV-S soybean L-a-phosphatidylcho-
line) in water. Mitochondrial outer membranes (5–10 lg protein) and
small liposomes (1 mg lipid) were mixed with 5 mM HEPES, pH 7.4,
and dotted on a glass slide. Samples were dehydrated 3 h and re-
hydrated overnight with 150 mM KCl and 5 mM HEPES, pH 7.4, at
4C. Proteoliposomes were harvested with 0.5 ml of the same media
and stored at )80 C.
2.3. Immunoblotting
Proteins were separated by SDS–PAGE and electro-transferred onto
PVDF membranes. Indirect immuno-detection employed chemilumi-
nescence (Amersham) using HRP-coupled secondary antibodies. Mi-
tochondrial outer and inner membranes (0.5–2 lg per lane) were
probed with primary antibodies against mammalian VDAC1 (Cal-
biochem 31-HL, 1:2500), cytochrome oxidase subunit IV (Molecular
Probes A-6431, 1:1000) and a secondary anti-rabbit or anti-mouse
antibody (Jackson Immunoresearch, 1:5000).
2.4. Patch-clamp analysis
Patch-clamp procedures and analysis used were previously described
[7,13,18]. Brieﬂy, membrane patches were excised from proteolipo-
somes containing puriﬁed mitochondrial outer membranes after for-
mation of a giga-seal using micropipettes with 0.4 lm diameter tips
and resistances of 10–20 MX at room temperature. Unless otherwise
stated, the solution was symmetrical 150 mM KCl and 5 mM HEPES,blished by Elsevier B.V. All rights reserved.
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the patch-clamp technique [19] using an Axopatch 200 ampliﬁer.
Voltages are reported as pipette potentials. The conductance was
typically determined from total amplitude histograms of 30 s of current
traces at +20 mV. MAC activity is distinct from VDAC and TOM
channels [13]. Currents were assigned as MAC if the conductance was
>1.5 nS and voltage independent. pClamp version 8 (Axon Instru.)
and WinEDR v2.3.3 (Strathclyde Electrophysiological Software;
courtesy of J. Dempster, University of Strathclyde, UK) were used for
current analysis. Hill coeﬃcients were determined as described by
Moczydlowski [20].Fig. 1. Fast blockade of MAC by dibucaine. (A) Immunoblots show
the presence of the outer membrane protein VDAC but not the inner
membrane protein cytochrome oxidase subunit IV (CoxIV) in the
outer membranes (OM, 2 lg) puriﬁed from mitochondria of apoptotic
FL5.12 cells. Inner membranes (IM, 2 lg) are the positive control for
CoxIV. (B) Representative current trace of a MAC recorded at +20
mV with 2 kHz ﬁltration is shown 10 s after perfusion of the bath with
50 lMDibucaine. o and c indicate open and closed conductance states.
(C) The dibucaine induced closure of MAC is reversible. Current traces
(right) and total amplitude histograms (left) of MAC are shown before
and after perfusion with media containing 200 lM dibucaine and after
perfusion with 150 mMKCl and 5 mMHEPES to wash out dibucaine.
o and c correspond to open and closed conductance states.3. Results and discussion
MAC is a potential therapeutic target because of its putative
role in the commitment step of apoptosis, i.e., the release of
cytochrome c. However, there is no pharmacological proﬁle
for MAC at this time. Apoptotic hematopoietic cells were used
in this study to investigate the eﬀect of a variety of agents on
MAC activity. Apoptosis was induced by withdrawal of in-
terleukin-3 (IL-3) from the leukemia cell line FL5.12. MAC
activity is detected and cytochrome c is released from the mi-
tochondria of these cells 12 h after IL-3 withdrawal [7,13,14].
Outer membranes were puriﬁed from mitochondria isolated at
this time. The Western blot of Fig. 1A shows the presence of
the outer membrane protein VDAC and essentially none of the
inner membrane protein cytochrome oxidase subunit IV in the
preparations; there is little contamination of the outer mem-
branes by inner membranes. MAC activity was examined using
patch-clamp techniques on proteoliposomes formed by the
fusion of these outer membranes with liposomes (see Section
2). MAC is a heterogeneous channel with a variable high
conductance and several substates. In this study, the eﬀects of
a variety of pharmacological agents were determined on MAC
activity with a conductance of 1.5–5 nS and a long-lived open
state [7,13].
MAC is exquisitely regulated by Bcl-2 family proteins but
the molecular identity of this channel is not yet known. MAC
is never detected in apoptotic cells overexpressing Bcl-2. In-
terestingly, MAC-like activity is detected in yeast expressing
Bax and in membrane patches containing recombinant Bax
[13]. These ﬁndings suggest that Bax might be involved with
MAC activity. Dibucaine and propranolol (100–200 lM)
prevent the release of cytochrome c induced by recombinant
Bax plus t-Bid or BH3 peptide [21], but they do not prevent
Bax insertion into membranes.
The eﬀect of dibucaine on MAC was examined because Bax
may be a component of the MAC. As shown in Fig. 1B, the
current ﬂow through MAC is rapidly reduced upon perfusion
of the bath with 50 lM dibucaine. The blockade of MAC by
dibucaine is reversible as removal of dibucaine from the bath
usually restores the high conductance. The total amplitude
histograms and current traces of Fig. 1C illustrate this re-
versible inhibition in another patch containing MAC. The
blockade is not voltage dependent as the current voltage curves
are linear between +40 and )40 mV (not shown). The blockade
of MAC by dibucaine is similar in partially puriﬁed fractions
of MAC from apoptotic HeLa cells treated with staurosporine
(unpublished results of Dejean, Martinez-Caballero, Antons-
son & Kinnally).
Dibucaine causes a fast blockade of MAC, similar to the
eﬀects of diethylamine on sodium channels [22]. These block-
ade events are rapid as there is no discernable increase in noiseat 2 kHz accompanying the decrease in conductance in the
presence of dibucaine (not shown).
Like dibucaine, propranolol blocks the release of cyto-
chrome c induced by Bax plus either a synthetic BH3 peptide
or t-Bid [21]. Propranolol also blocks the current ﬂow through
MAC as shown in the current traces and amplitude histograms
of Fig. 2A. The inhibition of MAC conductance by propran-
olol is not voltage dependent as the current voltage curves are
linear between +40 and )40 mV (not shown). In contrast to
dibucaine, the eﬀects of propranolol on MAC activity are not
reversible as removal by perfusion of the bath does not restore
MAC’s conductance. Triﬂuoperazine also blocks MAC as
shown in the current traces and amplitude histograms of
Fig. 3. Inhibitory eﬀects of dibucaine, propanolol and triﬂuoperazine.
% Inhibition of conductance (% mean conductance with/without drug)
is plotted as a function of the log concentration [M] of dibucaine,
propranolol and triﬂuoperazine (A), and lidocaine and cyclosporine A
(B). The data are best ﬁt with lines for dibucaine, propranolol and
triﬂuoperazine with IC50 of 39, 52 and 0.9 lM and correlation coeﬃ-
cients (R2) of 0.99, 0.96 and 0.95, respectively. The correlation coeﬃ-
cients (R2) for the best ﬁts for lidocaine and cyclosporine A are 0.92
and 0.90, respectively.
Fig. 2. Propranolol and triﬂuoperazine block the conductance of
MAC. Current traces (right) and total amplitude histograms (left) of
two patches in which MAC was recorded at )30 mV before and after
application of (A) 200 lM propranolol and (B) 10 lM triﬂuoperazine
(TFP). c and o indicate closed and open conductance states.
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not voltage dependent or reversible.
The mechanism of blockade of MAC by dibucaine is not the
same as that of triﬂuoperazine and propranolol. Propranolol
and triﬂuoperazine decrease the conductance of MAC, but the
eﬀects are not reversible. Repeated washing out of triﬂuoper-
azine and propranolol does not result in a re-opening of the
channel. Therefore, the mechanism(s) underlying the eﬀects of
triﬂuoperazine and propranolol are likely either a tight binding
that ‘‘plugs’’ the pore of MAC or a destabilization of the open
state. The latter is more likely as the eﬀects are not reversed
several minutes after removal of the agents. Hence, the eﬀects
of triﬂuoperazine and propranolol are similar to the Type 2
eﬀects of cytochrome c [7].
The three pharmacological agents inhibit MAC in a dose-
dependent manner as shown in % inhibition curves of Fig. 3A.
The IC50 for triﬂuoperazine, propranolol, and dibucaine
blockade of MAC (and Hill coeﬃcients) are 0.9 lM (1.4 0.2),
52 lM (2.1 0.2), and 39 lM (1.3 0.1). While the mechanism
of blockade for the three agents is not identical, the Hill co-
eﬃcients for all of these inhibitors are more than 1. Typically,
this ﬁnding indicates that there is some degree of cooperativity
involved in the blockade for each of these cationic amphiphilic
drugs.
Cyclosporine A and lidocaine have limited eﬀects on MAC
activity as shown in Fig. 3B. The IC50 for these agents are mM
to M, which is much larger than that of dibucaine, propranolol
and triﬂuoperazine. The structures of lidocaine and dibucaine
are similar [21], but 300 lM lidocaine has little eﬀect on MAC
activity. Cyclosporine A (0.1–1 lM) blocks the PTP in mito-
chondria [23–25]. However, the putative PTP inhibitors tri-
ﬂuoperazine (10–20 lM) and dibucaine (50–100 lM) [26] also
block MAC, but the IC50 for MAC is lower than it is for the
PTP. Similarly, propranolol blocks MCC, an electrophysio-
logical manifestation of the PTP, but the IC50 is 700 lM [27]
compared to 50 lM for MAC. Interestingly, triﬂuoperazine
and propranolol block apoptosis in some cell lines [28,29].
Furthermore, triﬂuoperazine (10–20 lM) and dibucaine (50–
100 lM) also block mitochondrial depolarization induced by
glutamate in neurons [26]. Hoyt et al. [26] interpreted thisprotection as an inhibition of the permeability transition by
these agents. Nevertheless, 0.1–1 lM cyclosporine A blocks the
PTP in mitochondria [23–25] and up to 10 lM has no eﬀect on
MAC activity. These ﬁndings suggest that MAC and the PTP
are independent.
While the IC50 for triﬂuoperazine is in the high nanomolar
range, none of these drugs are highly speciﬁc. In fact, triﬂuo-
perazine, propranolol and dibucaine also inhibit mitochondrial
protein import [30] and inhibit the permeability transition in-
duced by signal peptides, which likely corresponds to opening
of the protein import channel (translocase of the inner mem-
brane, Tim) [21,31,32]. While lidocaine and dibucaine increase
membrane ﬂuidity [33,34], lidocaine has no eﬀect on MAC. In
contrast, there are conﬂicting reports of the eﬀects of pro-
pranolol on membrane ﬂuidity [33,35]. As dibucaine and
propranolol may have opposing eﬀects on bilayer ﬂuidity,
MAC opening may be somehow sensitive to this parameter.
Others have suggested a role for lipids in the release of cyto-
chrome c [36–38] and the molecular identity of MAC is not
known. These agents may modify as yet unidentiﬁed lipid
components of the MAC. In fact, the results of Polster et al.
[21] suggest that dibucaine and propranolol inhibit Bax-in-
duced permeability changes through a direct interaction with
the lipid membrane. Finally, dibucaine and triﬂuoperazine
inhibit phospholipase A2 [39], which again may implicate a
role for lipids in MAC activity. However, it is unlikely that
38 S. Martinez-Caballero et al. / FEBS Letters 568 (2004) 35–38there is functional phospholipase A2 in the reconstituted sys-
tem used in this study.
Triﬂuoperazine, dibucaine and propranolol reduce the con-
ductance of MAC below 1.3 nS. It will be important to com-
pare these agents with those identiﬁed as blockers of Bax
channels [21,40], as Bax may be a component of MAC. Our
previous studies indicate that cytochrome c does not aﬀect
MAC if the conductance is below 1.9 nS [7], i.e., cytochrome c
likely does not transit a pore with a conductance below 1.9 nS.
Hence, triﬂuoperazine, dibucaine, and propranolol eﬀectively
eliminate the MAC’s permeability for cytochrome c and
should short circuit the death cascade. Future studies will in-
clude examination of the eﬀect of pharmacological agents that
modify MAC on the progression of apoptosis in vitro and in
vivo. Ultimately, agents may be identiﬁed that reduce the
volume of cell death associated with, e.g., stroke and myo-
cardial infarction.
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